Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In conclusion, there are solid data demonstrating that it is safe and effective to start ART on the day of diagnosis or at the time of linkage—ART should preferably be started within 48-72 hours of diagnosis, even before laboratory results are obtained. Evidence from the DIAMOND trial and from observational studies in real-world settings demonstrate that immediate ART initiation leads to earlier viral suppression and increased retention in care with sustained virologic response.
High efficacy rates were demonstrated in the United States from clinical experience with DTG-based and BIC-based regimens and with DRV/COBI/FTC/TAF in the first phase III trial for the rapid care model (DIAMOND trial). There are limited data to support that these regimens are as effective in patients with PrEP failure and baseline M184V/I mutations. Of importance, there have been no reported cases to date of INSTI or DRV resistance or regimen modifications needed from the clinics in San Francisco, New Orleans, and Chicago or from the DIAMOND trial.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.